Hints and tips:
Related Special Reports
...WPP’s Ogilvy advertising agency is creating a division specialising in online “health influencers” to help pharmaceutical companies tap a trend towards personalised health and combat misinformation....
...The jab’s variant formulation was approved by the US Food and Drug Administration earlier this month....
...Factors that need to be considered include the number of people suffering from vaccine fatigue and demand for Paxlovid beyond that of the US government when the drugmaker starts selling it commercially in...
...As such, it is not cheap: in the US, it costs $300,000 per patient, per year....
...A Humira biosimilar from Teva Pharmaceuticals working with Alvotech earlier this year became the first drug that the US Food and Drug Administration granted interchangeable status, which lets pharmacists...
...The US does not have a specific insider trading prohibition. Rather it relies on anti-fraud statutes based on theories of theft and misuse of information....
...“It was one of the most epic episodes ever in pharmaceuticals history: you got an accelerated approval of a product that didn’t have a completed phase 3 trial....
...The case is the latest in a series of intellectual property battles that companies are fighting around the world over mRNA technology, which has helped generate billions in revenues for the pharmaceuticals...
...But within a year of the US Food and Drug Administration’s 2021 approval of the weight-loss drugs known as GLP-1 agonists, the threat of them breaking WW’s business model became clear....
...The US healthcare company said on Friday that it would pay $335 a share in cash to acquire Shockwave, which specialises in manufacturing a catheter-based treatment for patients with calcified arteries....
...US-based hedge fund Shah Capital wrote to the Novavax board on Monday to push for the instalment of two new independent board directors....
...Regulators in Europe and other countries including the US have been scrutinising more deals after accusations they had been too lax about relatively small transactions with potential for significant market...
...Pharmaceuticals groups Pfizer and Moderna, which have both faced criticism from fringe groups over their Covid-19 vaccines, also spent heavily on security for their CEOs last year....
...Pfizer shares tumbled more than 8 per cent after the US drugmaker forecast 2024 revenues that were below consensus estimates, as the company attempts to chart a future for growth without blockbuster Covid...
...Pfizer is abandoning its plans for a weight loss pill to be taken twice a day after trials showed it caused significant side effects, in a setback to the US drugmaker’s effort to enter the fast-growing market...
...The drug is not yet approved in the US or Europe....
...Regulators have taken notice after a study sparked fresh doubts over the usefulness of a Covid drug made by US pharma group Merck, raising questions about the costly procurement of antivirals during the...
...They have done so by selling crisps, chocolates and sweetened drinks that have contributed to surging mass obesity, particularly in the US. But their gig may be up....
...EU regulators will order US biotech Illumina to sell cancer test developer Grail after it bought the $8bn company without the approval of Brussels, according to three people with direct knowledge of the...
...It will acquire the rights to sell it in the US, where there is a $15bn market for IBD, and in Japan....
...Horizon had also attracted interest from French drugmaker Sanofi and US pharma group Johnson & Johnson....
...The US drugmaker reduced guidance for Paxlovid revenues by about $7bn this year after the US government returned about $4.2bn worth of treatment....
...Last month, Illumina disclosed that the US Securities and Exchange Commission was investigating its acquisition of Grail....
...The UK pharmaceutical retailer’s transfer of £4.8bn of pension obligations to insurer Legal & General brings its potential sale by owner Walgreens Boots Alliance one step closer....
...He said chancellor Jeremy Hunt and the health department should address conflicts with the pharmaceutical industry over drug prices and hurdles to running clinical trials in the NHS....
International Edition